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Abstract
Background: To study the incidence of vancomycin-associated acute kidney injury (VA-AKI) in Hong Kong and
identify risk factors for VA-AKI.
Method: Patients with vancomycin prescription and blood level measurement in 2012–2016 were identified using
the Hong Kong Hospital Authority Clinical Data Analysis and Reporting System. Acute kidney injury was defined
using KDIGO criteria. Patients without creatinine measurements, steady-state trough vancomycin level or who had
vancomycin treatment < 3 days were excluded. Results were analyzed using SPSS version 22.0. Logistic regression
was used to identify the predictors for VA-AKI. Odds ratio and 95% confidence interval were estimated.
Results: One thousand four hundred fifty patients were identified as VA-AKI from 12,758 records in Hong Kong in
2012–2016. The incidence was respectively 10.6, 10.9, 11.3, 12.2, 11.2% from 2012 to 2016. The incidence of VA-AKI
was 16.3, 12.2, 11.3 and 6.2% in patients aged 1–12, 12–60, elderly aged > 60 and newborn and infants, respectively.
Baseline creatinine, serum trough vancomycin level, systematic disease history including respiratory failure,
hypertension, congestive heart failure, chronic renal failure, anemia and type II diabetes, and concomitant diuretics,
piperacillin-tazobactam (PTZ) and meropenem prescription were significantly higher in VA-AKI patients older than
12 years. Logistic regression showed that older age group, higher baseline creatinine, serum trough vancomycin
level, respiratory failure, chronic renal failure and congestive heart failure, concomitant diuretics, PTZ and
meropenem prescription, and longer hospital stay were all associated with increased risk of VA-AKI.
Conclusion: The incidence of VA-AKI in Hong Kong is low but shows no decline. Patients with higher baseline
creatinine, multi-organ diseases and multiple drugs administration should have their vancomycin level monitored to
decrease the risk of VA-AKI.
Keywords: Vancomycin, Acute kidney injury
Background
Methicillin-resistant Staphylococcus aureus (MRSA) has
gained considerable attention due to its high morbidity,
limited effective treatments available and increased inci-
dence [1]. Vancomycin has been recommended as the
first line treatment for MRSA infections by American,
European, and Chinese guidelines for infectious diseases
control and management control for antibiotics [2–5].
However, the significant nephrotoxicity limits the use of
vancomycin in daily clinical practice. It has been
reported the incidence of VA-AKI ranges from 0% to
over 40% [6].
AKI is one of the examples of nephrotoxicity that
accounts for about 1.7 million deaths every year world-
wide. The consequences of AKI can be severe, ranging
from hospitalization to life-long dialysis and transplant-
ation. From a recent meta-analysis, the pooled incidence
of AKI was 19.4% in eastern Asia [7]. Drugs are the third
main cause of AKI [8]. The prognosis in drug-associated
AKI is poor, especially in critically ill patients.
In Hong Kong, there is limited published literature on
the incidence of drug-induced nephrotoxicity. A previ-
ous study reported an incidence of 23.1% for VA-AKI in
a hospital [9]. A systematic population-wide study is
clearly needed, in view of the serious implications of this
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potentially preventable and reversible condition. There-
fore, we investigated the incidence of VA-AKI in Hong
Kong from 2012 to 2016, characterized patients with
VA-AKI as well as identified predictors for the develop-
ment of VA-AKI.
Methods
Study design and data sources
A retrospective study was conducted using Clinical Data
Analysis and Report System (CDARS), a database man-
aged by the Hong Kong Hospital Authority (HA). HA is
the sole public hospital service provider in Hong Kong.
More than 90% of Hong Kong residents use the public
hospital services [10]. CDARS captures patient records
in Hong Kong in all public hospitals and outpatient
clinics since 1993. This database provides a convenient
platform for pharmaco-epidemiological studies [11].
All patients’ records with vancomycin prescription and
measurement of serum drug level from January 2012 to
December 2016 in Hong Kong were retrieved from
CDARS. Demographics, laboratory parameters, con-
comitant medications and co-morbidities were collected
as the covariates. Patients with vancomycin prescription
and steady-state serum trough vancomycin level were in-
cluded as the exposure status. Patients who had no base-
line and follow-up concentration of creatinine within 48
h, vancomycin treatment < 3 days or steady state serum
trough vancomycin level were excluded. Trough concen-
trations were defined as the results from the samples
taken within 1 h of the next due dose. The first trough
concentration was measured after 3 days of vancomycin
administration.
Definition of AKI
With the use of Kidney Disease Improving Global
Outcomes (KDIGO) criteria [12], patients with AKI were
identified as increase in serum creatinine (SCr) by 0.3
mg/dL or more within 48 h, or as a 1.5~1.9 times in-
crease in SCr from baseline. These patients were at least
of stage I in severity. Stage II was defined as 2~2.9 times
increase in SCr from baseline. Stage III was defined as 3
times increase in SCr from baseline or increase in SCr to
≥4mg/dL. Vancomycin-associated AKI was the main
outcome for the study. Patients without VA-AKI were
classified as non-VA-AKI group.
Statistical analysis
IBM SPSS statistics version 22.0 (IBM SPSS Statistics,
Armonk, NY, USA) was used for data analysis. Descrip-
tive statistics were expressed as frequency for categorical
data or median (interquartile range) for continuous
variables. With reference to a vancomycin therapeutic
guideline [5], vancomycin concentration was categorized
into 4 groups: < 10.0 mg/L, 10.0~15.0 mg/L, 15.0~20.0
mg/L, > 20.0 mg/L. Continuous variables were compared
among groups using one-way ANOVA and Kruskal-
Wallis tests as appropriate. Categorical variables were
compared among groups using Pearson Chi-square test.
Logistic regression was used to estimate odd ratios
(ORs) and 95% confidence interval (CI). Firstly, univari-
ate logistic models were used to explore the relationship
between VA-AKI and risk factors, including gender, age,
route of administration, baseline creatinine, tough
vancomycin level, concomitant drugs, length of stay and
death in hospital. Secondly, to determine whether there
was significant collinearity between continuous variables,
collinearity diagnostics were performed using variance
inflation factor (VIF) and tolerance values. If tolerance
value is close to zero or VIF is greater than 10, there
may be multi-collinearity. Thirdly, four models adjusted
by different confounders were applied to analyse the
possible predicators. Model 1: adjusted for demographics
(age, sex); Model 2: additionally adjusted for comorbidi-
ties; Model 3: additionally adjusted for medications;
Model 4: additionally adjusted for baseline creatinine
and length of stay. Predictor variables were entered if
P < 0.05 and removed if P > 0.10 in the stepwise model.
A two-tailed P < 0·05 was considered statistically signifi-
cant. A two-tailed P < 0.05 will be considered statistically
significant.
Results
A total of 12,758 patients were included in this study
from 2012 to 2016 in Hong Kong (Fig. 1). The median
age of patients with VA-AKI was 72 years old, and 64.2%
of cases were male. The prescription of vancomycin in-
creased gradually and doubled in 2016 compared with
2012. The incidence of VA-AKI remained at approxi-
mately 11.4% (Table 1).
Table 2 shows the characteristics of patients with VA-
AKI stratified by age group. The incidence of VA-AKI in
patients aged 1 to 12 was the highest (16.3%), following
patients aged 12 to 60 (12.2%), elderly aged over 60
(11.3%) and newborn and infants (6.2%). The median
age of VA-AKI patients was slightly younger than pa-
tients without VA-AKI in elderly group, yet older than
patients without VA-AKI in patients less than 60 years
old. There was no significant gender difference between
VA-AKI and non-VA-AKI groups in all age groups. The
main route of administration was injection and paren-
teral, with several cases of oral, eye drop and intraperito-
neal route. The incidence of VA-AKI was distinctively
higher in newborn and infants receiving parenteral ad-
ministration (P < 0.001). The baseline creatinine and
trough vancomycin concentration in the VA-AKI group
were significantly higher than non-VA-AKI group in pa-
tients older than 12 years old (P < 0.001). However, there
were no significant difference in patients aged under 12.
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Along with the increase of trough vancomycin level, the
incidence of VA-AKI either in cumulative incidence or
in each AKI stage showed a significantly upward trend
(P < 0.001) (Fig. 2). Compared to non-VA-AKI group,
more patients with VA-AKI aged over 12 had comorbid-
ities including respiratory failure, essential hypertension,
congestive heart failure, chronic renal failure, anaemia
and type II DM. There were more comorbidities in VA-
AKI patients between 12 to 60 years old compared with
non-VA-AKI group in the same age group. Patients with
VA-AKI aged over 12 were more likely to receive di-
uretics, piperacillin-tazobactam (PTZ) and meropenem,
while more angiotensin converting enzyme inhibitors
(ACEI) prescripts were found in patients with VA-AKI
from 1 to 12 years old, more ACEI, angiotensin II recep-
tor blocker (ARB), non-steroidal anti-inflammatory
drugs (NSAID) prescripts in VA-AKI group from 12 to
60 years old, and more aminoglycoside and amphotericin
B prescripts in VA-AKI patients over 60 years old. Pa-
tients over 60 years old with VA-AKI were hospitalized
for longer duration. VA-AKI group had a significantly
higher mortality in hospital compared with non-VA-AKI
group.
Logistic analysis shows the possible risk factors associ-
ated with VA-AKI (Table 3). Using both univariate logis-
tic model and adjusted logistic models showed that
older age, baseline creatinine, trough vancomycin level,
the comorbidities including essential hypertension, an-
aemia, respiratory failure, type II DM, chronic renal fail-
ure and congestive heart failure, concomitant drugs
including diuretics, ACEI, ARB, PTZ, and meropenem
were all associated with higher risk for the development
of VA-AKI. Regarding collinearity, the highest VIF and
the lowest tolerance values were 1.016 and 0.87,
Fig. 1 A flow diagram for inclusion of study samples
Table 1 Incidence and demographic characters of patients with VA-AKI in Hong Kong from 2012 to 2016
2012 2013 2014 2015 2016
Annual admissions 1,466,788 1,508,489 1,532,926 1,592,148 1,629,346
Vancomycin prescription 3310 3510 4132 5597 6694
Enrolled patients 1542 1709 2446 3374 3687
Male 63.1% 62.5% 62.9% 63.7% 64.0%
Female 36.9% 37.5% 37.1% 36.3% 36.0%
Age 71.7 (52.8, 83.0) 71.6 (55.8, 81.9) 73.8 (58.5, 83.4) 71.8 (58.1, 83.5) 76.5 (62.1, 85.7)
VA-AKI cases 164 186 276 410 414
Incidence of VA-AKI 10.6% 10.9% 11.3% 12.2% 11.2%
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respectively, which suggests the absence of significant
collinearity. Compared with newborns and infants, older
age groups had lower ORs for development of VA-AKI
(OR of children 1 to 12 years of age: 2.93 (95%CI [1.63,
5.27], OR of adults and adolescents above 12 years of
age: 2.09 (95%CI [1.39, 3.13], OR of elderly patients: 1.91
(95%CI [1.29, 2.84], respectively). Most of these predica-
tors had positive relationships with VA-AKI, yet, urinary
tract infection had a negative relationship with VA-AKI
(OR: 0.75 (95%CI [0.66, 0.86]). After adjusted for gender,
age, comorbidities, concomitant drugs, baseline creatin-
ine and length of stay in various models with increasing
confounders, vancomycin, especially vancomycin con-
centration over 10 were still significant predicators for
VA-AKI. Compared to the vancomycin level less than
10.0 mg/L group, higher vancomycin level had higher
OR for VA-AKI onset in univariate logistic model (OR
of 10.0~15.0 level: 1.55 (95%CI [1.34, 1.81], OR of
15.1~20.0 level: 2.50 (95%CI [2.13, 2.93], OR of > 20.0
level: 3.89 (95%CI [3.34, 4.53], respectively).
Discussion
In this study involving 12,578 patients on vancomycin,
the incidence of VA-AKI was 11.4% in Hong Kong in
2012–2016. Compared with non-VA-AKI group, VA-
AKI patients older than 12 years had significant higher
level or frequency in the baseline creatinine, trough
vancomycin level, systematic disease history including
respiratory failure, essential hypertension, congestive
heart failure, chronic renal failure, anaemia and type II
DM, and concomitant drugs usage including diuretics,
PTZ and meropenem. VA-AKI group had a significantly
higher mortality in hospital compared with non-VA-AKI
group. The incidence of VA-AKI increased with in-
creased vancomycin level. Stepwise logistic regression
showed that older age group, higher vancomycin level,
comorbidities including respiratory failure, chronic renal
failure and congestive heart failure, concomitant drugs
including diuretics, PTZ and meropenem and length of
stay were all independent risk factors for the develop-
ment of VA-AKI.
This study is the first large scale investigation of VA-
AKI in Hong Kong. In previous studies, the incidence of
VA-AKI in Chinese varied from 2.4 to 45% [9, 13–16]
(Additional file 1: Table S1). The difference of estimated
incidence is due to different populations, sample sizes,
inclusion criteria and AKI definition. In USA, the inci-
dence of VA-AKI declined from 42.6% in 2007 to 14.1%
in 2017 [17, 18]. This might be due to doctors’ aware-
ness of the toxicity of vancomycin and improvements in
vancomycin purity. Our study reports a lower incidence
of VA-AKI than the previous study [9], since the large
database is less prone to publication and other biases.
In the literature, nephrotoxicity occurs in 1–9% of
neonates receiving currently recommended doses, and
6–14% of paediatric patients [19–21]. Since these studies
were all based on different population, the incidence of
VA-AKI cannot be compared. Our study compared the
incidence of VA-AKI in different age group based on the
same population. By age group, the order of incidence
from high to low was children from 1 to 12 years old
(16.3%), adolescents above 12 years of age and adults
(12.2%), elderly patients aged over 60 years (11.3%), new-
borns and infants (6.2%). The characters of young pa-
tients with VA-AKI were different from elderly patients.
The median of trough vancomycin in patients under 60
years old were all lower than 10 mg/L, yet the incidence
of VA-AKI still accounted for a sizeable proportion. In
new-borns and infants receiving parenteral administra-
tion the incidence of VA-AKI was distinctively higher.
There have been studies on the risk factors for VA-
AKI in the past [22–24]. Like previous studies, a positive
correlation between VA-AKI and increasing vancomycin
trough concentrations and baseline serum creatinine was
Fig. 2 The incidence of vancomycin associated AKI stratified by vancomycin level (mg/L) and AKI stage
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Table 3 Predicators for VA-AKI in Hong Kong
OR Model 1 Model 2 Model 3 Model 4
Male 0.96 (0.86, 1.08) – – – –
Age
Newborn and infants Reference – – – –
Children 1 to 12 years of age 2.93 (1.63, 5.27)* – – – –
Adults and adolescents above 12 years of age 2.09 (1.39, 3.13)* – – – –
Elderly patients 1.91 (1.29, 2.84) – – – –
Chemistry profile
Baseline creatinine 1.00 (1.00, 1.00)* 1.00 (1.00, 1.00)* 1.00 (1.00, 1.00)* 1.00 (1.00, 1.00)* –
Trough vancomycin level 1.04 (1.04, 1.05)* 1.05 (1.04, 1.05)* 1.04(1.04, 1.05)* 1.04 (1.04,1.05)* 1.04 (1.04,1.05)*
Classification of vancomycin level (mg/L)
< 10.0 Reference Reference Reference Reference Reference
10.0~15.0 1.55 (1.34, 1.81)* 1.68 (1.44, 1.96)* 1.63 (1.39, 1.92)* 1.62 (1.38,1.89)* 1.64 (1.40,1.93)*
15.1~20.0 2.50 (2.13, 2.93)* 2.75 (2.33, 3.24)* 2.62 (2.21, 3.11)* 2.61 (2.20,3.08)* 2.62 (2.21,3.11)*
> 20.0 3.89 (3.34, 4.53)* 4.29 (3.67, 5.02)* 3.93 (3.34, 4.63)* 4.05 (3.45,4.77)* 4.07 (3.46,4.79)*
Comorbidities
Pneumonia 1.06 (0.94, 1.19) 1.07 (0.96, 1.21) – – –
Essential hypertension 1.23 (1.10, 1.38)* 1.33 (1.18, 1.50)* – –
Urinary tract infection 0.87 (0.77, 0.98)# 0.88 (0.77, 1.00) – – –
Fever 0.97 (0.86, 1.09) 0.98 (0.87, 1.11) – – –
Anemia 1.29 (1.14, 1.45)* 1.30 (1.15, 1.48)* – – –
Respiratory failure 1.39 (1.22, 1.58)* 1.39 (1.22, 1.58)* – – –
Type II DM 1.25 (1.10, 1.41)* 1.28 (1.13, 1.46)* – – –
Sepsis 1.03 (0.90, 1.19) 1.05 (0.91, 1.20) – –
Chronic renal failure 3.17 (2.72, 3.70)* 3.18 (2.72, 3.71)* – – –
Congestive heart failure 1.56 (1.37, 1.79)* 1.63 (1.42, 1.87)* – – –
Concomitant drugs
Inotropic agents 1.26 (1.05, 1.50)# 1.28 (1.07, 1.53)# 1.19 (0.99,1.43) – –
Diuretics 1.71 (1.51, 1.94)* 1.72 (1.51, 1.95)* 1.49 (1.31,1.70)* –
ACEI 1.25 (1.11, 1.41)* 1.27 (1.12, 1.43)* 1.11 (0.98,1.27) – –
ARB 1.46 (1.20, 1.77)* 1.47 (1.21, 1.79)* 1.15 (0.94,1.42) – –
PTZ 1.39 (1.24, 1.57)* 1.41 (1.25, 1.59)* 1.39 (1.23,1.57)* – –
Meropenem 1.29 (1.16, 1.45)* 1.29 (1.15, 1.44)* 1.23 (1.10,1.39)* – –
Aminoglycoside 1.71 (0.96, 1.22) 1.07 (0.95, 1.21)# 1.05 (0.94,1.18) – –
Cefepime 1.31 (1.01, 1.71) 1.29 (0.99, 1.69) 1.04 (0.92,1.18) –
Amphotericin B 0.84 (0.73, 0.98)# 0.84 (0.72, 0.97) 1.24 (0.95,1.63) – –
NSAIDs 1.00 (1.00, 1.00)# 1.00 (1.00, 1.00) 0.93 (0.80,1.09) – –
Length of Stay 0.97 (0.86, 1.09) 0.98 (0.87, 1.11) 1.00 (1.00,1.00) 1.00 (1.00,1.00)# –
Data is expressed as odds ratio (95% confidence interval)
-Not available or not in the equation
Model 1: adjusted for age and gender
Model 2: additionally, adjusted for comorbidities;
Model 3: additionally, adjusted for medications;
Model 4: additionally, adjusted for baseline creatinine and length of stay
*p < 0.001 #p < 0.05
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found in this study. The association between age and
VA-AKI was controversial, mostly with a positive correl-
ation [24]. While some studies explored after controlling
for comorbid condition, medications and renal function,
age is not associated with AKI [25]. In this study, we
found age was correlated with VA-AKI, yet compared
with new-borns and infants age group, older age group
had less OR for development of VA-AKI. Concomitant
administration of diuretics, PTZ and meropenem could
increase the incidence of nephrotoxicity [22, 26, 27], ex-
cept concomitant NSAIDs seems to have a protective
role for VA-AKI. In each age group, VA-AKI incidence
was lower in patients with concomitant NSAIDs. We
confirmed that concomitant chronic renal failure, con-
gestive heart failure and respiratory failure increased the
risk for VA-AKI, as in a previous study in China [15].
Although vancomycin administrated by eye-drops, oral
and intraperitoneal has low bioavailability, a previous
study reported AKI development was related with the
usage of topical fortified gentamicin and vancomycin
eyedrops [28]. Similarly, serum concentration of
vancomycin could also be observed in VA-AKI group in
different routes of administration in this study. The inci-
dence and mechanism of VA-AKI in uncommon routes
of administration remains uncertain, yet the possible risk
for AKI development should be noticed.
Several explanations have been put forth on the cause
of VA-AKI, including impurities in vancomycin [29],
critically-ill patients with complications and on multiple
drugs, and lack of suitable control patients. A random-
ized controlled trial was conducted to identify the rela-
tionship between vancomycin and the development of
AKI. Patients were randomized to continuation of dose-
optimized vancomycin or early switch to an alternative
antimicrobial agent. The incidence of AKI in both
groups was similar (32.7 to 31.4% [P = 0.89]) [30], but
this was a small study of 103 patients in a single center.
The strength of this study was that it was population-
based and territory-wide, and used a very large database.
In the limited literature, the incidence of AKI in Hong
Kong was reported as 11.7% [31], similar to the
incidence of VA-AKI in our study. It provides good
evidence that dosing and monitoring practices of
vancomycin in Hong Kong are sound. However, there
were limitations. Since it was an observational study,
causation cannot be proven. Patients with VA-AKI could
have other reasons for AKI, such as comorbidities,
hypotension, sepsis and concomitant drugs. It is dis-
tinctly difficult to determine the actual risk factors of
VA-AKI.
Conclusion
In summary, the incidence of VA-AKI in Hong Kong is
low but shows no decline. As there is increased usage of
vancomycin to combat MRSA, there should be increased
awareness of VA-AKI. Patients with higher baseline
creatinine, chronic diseases and multiple drugs are at
risk of VA-AKI and should have their vancomycin level
monitored. Our findings facilitate the development of
strategies and guidelines to prevent vancomycin-
associated AKI.
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